enGene Appoints Lee Giguere as Chief Legal Officer and Corporate Secretary
- Lee Giguere's experience in leading the legal function of successful companies will support enGene's growth.
- enGene's lead program EG-70 is in a pivotal study for BCG-unresponsive non-muscle invasive bladder cancer.
- Giguere's expertise in late-stage development, product approvals, commercial launches, and strategic transactions will benefit enGene's initiatives.
- EG-70 is a novel, non-viral genetic medicine designed for ease-of-use by community urologists.
- None.
Experienced biotech executive brings public company expertise in legal, corporate governance, and compliance to support enGene during late-stage clinical development and anticipated future commercial launch of its lead program EG-70
"I am delighted to welcome Lee, an experienced public biotech legal executive, to enGene as we advance the development of EG-70 in our ongoing pivotal-stage LEGEND study in BCG-unresponsive non-muscle invasive bladder cancer," said Jason D.
Mr. Giguere previously served as Chief Legal Officer and Secretary of Obsidian Therapeutics, a clinical-stage cell and gene therapy company. Earlier, he was General Counsel and Secretary at Chiasma, where he led the legal, compliance, and human resource functions in support of the approval and launch of the company's acromegaly therapy and played a key role in the subsequent sale of the company. Previously, he was Deputy General Counsel and Assistant Secretary at Karyopharm Therapeutics through the approval and launch of its multiple myeloma therapy. Earlier in his career, Mr. Giguere held roles at Boston Scientific Corporation and in the business law practice of Goodwin Procter LLP. Mr. Giguere earned his Juris Doctor from Northeastern University School of Law and his Bachelor of Science in Business Administration from Northeastern University.
Mr. Giguere commented: "I am thrilled to join enGene as we work to transform the management of bladder cancer, beginning with BCG-unresponsive NMIBC. With EG-70, enGene has an opportunity to introduce a novel, non-viral, fit-for-purpose class of genetic medicine specifically designed for ease-of-use by the community urologists who are on the front lines of treating this patient group. I look forward to working alongside the team to further our mission, with the ultimate goal of fundamentally improving patient care."
About enGene
enGene is a late-stage biotechnology company mainstreaming genetic medicines through the delivery of therapeutics to mucosal tissues and other organs, whose lead program EG-70 is being evaluated in an ongoing pivotal study for patients with non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (Cis) who are unresponsive or naïve to treatment with Bacillus Calmette-Guérin (BCG). EG-70 was developed using enGene's proprietary Dually Derivatized Oligochitosan (DDX) platform, which enables penetration of mucosal tissues and delivery of a wide range of sizes and types of cargo, including DNA and various forms of RNA. enGene became a publicly traded company effective November 1, 2023, upon the completion of a business combination with Forbion European Acquisition Corporation, a special purpose acquisition company. For more information, visit enGene.com.
Some of the statements contained in this press release may constitute forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, and "forward-looking information" within the meaning of Canadian securities laws (collectively, "forward-looking statements"). enGene's forward-looking statements include, but are not limited to, statements regarding enGene's expectations, hopes, beliefs, intentions, goals, strategies, forecasts and projections. The words "anticipate", "appear", "approximate", "believe", "continue", "could", "estimate", "expect", "foresee", "intend", "may", "might", "plan", "possible", "potential", "predict", "project", "seek", "should", "would", and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements may include, for example, statements about: the future growth of enGene, the potential benefits of EG-70 and enGene's goal of mainstreaming gene therapy.
Many factors, risks, uncertainties and assumptions could cause the Company's actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statements, including, without limitation, the Company's ability to recruit and retain qualified scientific and management personnel, establish clinical trial sites and patient registration for clinical trials and acquire technologies complimentary to, or necessary for, its programs; the Company's ability to address diseases with high clinical needs; the Company's ability to retain commercial rights to EG-70 in
View original content to download multimedia:https://www.prnewswire.com/news-releases/engene-appoints-lee-giguere-as-chief-legal-officer-and-corporate-secretary-302047456.html
SOURCE enGene
FAQ
What is the name of the clinical-stage genetic medicines company mentioned in the PR?
What is the ticker symbol for enGene Holdings Inc.?
What is the lead program of enGene Holdings Inc.?
What is Lee Giguere's role at enGene Holdings Inc.?